Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania. Show more
Location: Four Tower Bridge, West Conshohocken, PA, 19428, United States | Website: https://www.madrigalpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
9.702B
52 Wk Range
$200.63 - $443.00
Previous Close
$435.27
Open
$436.30
Volume
254,627
Day Range
$426.00 - $438.74
Enterprise Value
9.029B
Cash
797M
Avg Qtr Burn
-76.85M
Insider Ownership
7.67%
Institutional Own.
-
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rezdiffra (Resmetirom) (MGL-3196) Details Non-alcoholic steatohepatitis , Liver disease | Approved Quarterly sales | |
Rezdiffra (Resmetirom) (MGL-3196) Details Liver disease, Cirrhosis | Phase 3 Data readout | |
Resmetirom (MGL-3196) Details Fatty liver disease, Liver disease | Phase 3 Update |